COMP <GO>
AVXL vs ENGN // ALTMAN Z-SCORE & DEBT/EQUITY
Anavex Life Sciences Corp. (NASDAQ) VS. enGene Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: AVXL 1
— ENGN 2
■ METRIC PARITY
LAST: $1.14 (-4.20%) • MKT CAP: $110.3M
balance-sheet
—
LAST: $1.45 (-5.23%) • MKT CAP: $102.5M
balance-sheet
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AVXL VS. ENGN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AVXL | ENGN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 2/9 | -1.00 | ENGN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 27.3 | 37.0 | -9.70 | ENGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $110.3M | $102.5M | $7.8M | AVXL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AVXL REV | ENGN REV | AVXL GROSS % | ENGN GROSS % | AVXL FCF | ENGN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $143.9M | $344.9M | — | — | -$39.0M | -$100.7M |
| FY 2024 | $148.1M | $174.4M | — | — | -$30.8M | -$49.2M |
| FY 2023 | $156.1M | $73.0M | — | — | -$27.8M | -$24.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AVXL // BETA —
ENGN // BETA —